INTRODUCTION: Hip resurfacing arthroplastys are a valid alternative for the treatment of degenerative hip disorders in young adults. Poor results and adverse soft tissue effects have been reported with high levels of chromium and cobalt, limiting its indications. Objective is to analyze clinical and functional survival results of the Durom system 10 years after its implementation in a public hospital. The hypothesis is that better results and survival are obtained in patients selected according to FDA criteria. MATERIAL AND METHODS: Retrospective cohort study of 83 patients, 91 hips in 76 men and 7 women operated between 2005 and 2013 with Durom-type prostheses. Demographic study, diagnosis, BMI, radiological study, serum chromium cobalt levels, functional assessment according to MPD and HSS, complications and survival at 10 years of follow-up. A cohort of active men under 65 years of age and heads over 48mm is selected. RESULTS: Follow-up time of 121 months with a range from 84 to 176 months. With a mean age of 52.78 years, with 4 deaths and loss of follow-up of 3 cases. There are 12 complications that require reoperation (14.45%) with 2 chronic infections, 4 femoral neck fractures, 4 acetabular loosening and 2 cases of pseudotumors. With an overall survival of 85.4% (71-91.9) and 87.85% (85.5-91.1) in the absence of infection. No statistical relationship between complications and neck narrowing and the angles of inclination of the components. In selected patients, 69 men and 73 hips, we obtained an overall survival of 91.82% and excluding infection of 93.18% at 10 years. CONCLUSIONS: The indication of the Durom system in the treatment of degenerative processes in selected active young patients presents better results and survival at 10 years, although somewhat lower than other highly indicated veneering models.